It has previously been shown that KIT mutations are enriched in “triple wild-type melanomas” (BRAF−, NRAS−, NF1−), which are less likely to be driven by an ultraviolet (UV) signature and carry significantly more copy-number segments and complex rearrangement events.26–28 The finding that the KIT mutation is enriched in this triple wild-type subgroup suggests that KIT constitutes a driver mutation in these tumors. The gene discussed is BRAF; the disease is melanoma.